Five stocks witnessing long built-up
Five stocks witnessing long built-up

Five stocks witnessing long built-up

Ganesh Pawar Article rating: 4.1

The market opened in green on May 06, 2021, overall volumes in futures & options currently stand at 4,87,14,614 contracts with a turnover of Rs. 44,63,162.54 crore.

Five stocks witnessing short built-up
Five stocks witnessing short built-up

Five stocks witnessing short built-up

Ganesh Pawar Article rating: 3.5

The market opened in green on May 06, 2021, overall volumes in futures & options currently stand at 4,87,14,614 contracts with a turnover of Rs. 44,63,162.54 crore.

Stocks likely to be in action today
Stocks likely to be in action today

Stocks likely to be in action today

Avalokita Pandey Article rating: 3.8

IDBI Bank: As per an official statement, Cabinet Committee on Economic Affairs (CCEA), on May 5, granted approval for the long-pending 'strategic disinvestment' of IDBI Bank Limited.  

Cadila Healthcare makes new 52-week high after extending JVA with Bayer PTE
Cadila Healthcare makes new 52-week high after extending JVA with Bayer PTE

Cadila Healthcare makes new 52-week high after extending JVA with Bayer PTE

Ganesh V Article rating: 3.6

Cadila Healthcare Limited announced today that it has signed an agreement to extend the tenure of the joint venture agreement (JVA) with Bayer (South East Asia) PTE Limited, one of the companies of Bayer Group, for a further period of two months. 

Bajaj Healthcare gains post launching drug effective for COVID patients
Bajaj Healthcare gains post launching drug effective for COVID patients

Bajaj Healthcare gains post launching drug effective for COVID patients

Ganesh V Article rating: 4.3

Bajaj Healthcare Limited (BHL) announced on Tuesday that it has launched Favijaj (Favipiravir), an antiviral drug used for treating patients suffering from the influenza virus. The company informed that the drug has proven to be quite effective over COVID patients.

Alembic Pharma slips over 4 per cent despite getting USFDA nod for Ophthalmic solution
Alembic Pharma slips over 4 per cent despite getting USFDA nod for Ophthalmic solution

Alembic Pharma slips over 4 per cent despite getting USFDA nod for Ophthalmic solution

Shruti Dahiwal Article rating: 4.0

Alembic Pharmaceuticals Limited, an Indian multinational pharmaceutical company, announced today that it has been granted final approval by US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic solution USP, 2 per cent and 0.5 per cent. 

NFO analysis: Tata Dividend Yield Fund
NFO analysis: Tata Dividend Yield Fund

NFO analysis: Tata Dividend Yield Fund

Henil Shah Article rating: 3.7

Tata Mutual Fund launched its dividend yield fund, Tata Dividend Yield Fund on May 3, 2021, and is currently open for subscription. Read onto find out more about it.

RSS
First18861887188818891891189318941895Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR